LONDON, Ontario--(BUSINESS WIRE)--Fortune Minerals Limited (TSX: FT) (OTCQB: FTMDF) (“Fortune” or the “Company”) (www.fortuneminerals.com) is providing an update of current work to advance the NICO Cobalt-Gold-Bismuth-Copper Project (“NICO Project”) in Canada…

DUBLIN--(BUSINESS WIRE)--The "Omega 3 Market Size, Share & Trends Analysis Report by Type (EPA, DHA, ALA), by Source (Marine Source, Plant Source), by Application, by Region, and Segment Forecasts, 2020-2027" report has been added to ResearchAndMarkets.com's …

With assets installed far from shore in harsh conditions, offshore wind turbine manufacturers and project operators are turning to new digital tools to optimize performance, boost power production, and minimize downtime. One such tool is the use of digital co…

Akers Biosciences, Inc. (the “Company”) (AKER), a developer of rapid health information technologies, today announced that Executive Chairman Christopher Schreiber will attend the “Hemp Industry Daily Forum” on Tuesday, December 10, 2019 as part of MJBizCon Week at the Las Vegas Convention Center in Las Vegas, Nevada. Akers Advisory Board member Bob Hoban is a featured speaker presenting on “International Opportunities” for Hemp operations within the Textiles to Cannabidiol (CBD) space.

Akers Biosciences, Inc. (the “Company”) (AKER), a developer of rapid health information technologies, today announced the closing of its previously announced registered direct offering of an aggregate of 1,366,856 shares of the Company’s common stock, at a purchase price of $3.53 per share priced at-the-market under Nasdaq rules. The gross proceeds to the Company from this offering was approximately $4.8 million, before deducting the placement agent’s fees and other offering expenses payable by the Company. The shares of common stock were offered by the Company pursuant to a "shelf" registration statement on Form S-3 (File No. 333-234449) previously filed with the Securities and Exchange Commission (the "SEC") on November 1, 2019, and declared effective by the SEC on April 7, 2020.

Akers Biosciences, Inc. (the “Company”) (AKER), a developer of rapid health information technologies, today announced that Premas Biotech, its partner in the development of a vaccine candidate that is seeking to address the COVID-19 pandemic, has successfully completed its vaccine prototype. Premas obtained transmission electron microscopic (TEM) images of the recombinant virus like particle (VLP) assembled in yeast during the past week which marks a significant milestone and is believed by Premas to be one of the first in the world for VLP of SARS-CoV-2 virus. Premas, which is primarily responsible for the development of the vaccine candidate through proof of concept, is collating data at this time and, collectively with Akers, moving forward with conversations with regulatory authorities in India and continuing to develop a regulatory strategy in the United States.

The collapse in oil prices to 21-year lows has led potential buyers of oil and gas fields to try and renegotiate deals already agreed at higher prices, with the first examples emerging of sellers having their hand forced.

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 5) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD )(presented ...

Today is shaping up negative for Aker BP ASA (OB:AKERBP) shareholders, with the analysts delivering a substantial...

Akers Biosciences, Inc. (the “Company”) (AKER), a developer of rapid health information technologies, today announced that its collaboration with Premas Biotech has successfully completed the milestone of obtaining clones of all three coronavirus antigens, Spike (S), Envelope (E), and Membrane (M) that they have selected for their vaccine candidate. Premas Biotech develops novel technologies and partners with global biopharmaceutical companies to build and develop novel biotherapeutic & vaccine candidates.

Akers Biosciences Inc., a South Jersey medical device company that recently joined the race to develop a COVID-19 vaccine, plans to raise $4.6 million in a public stock sale. The Thorofare-based company is selling 766,667 shares of its common stock at a purchase price of $6.00 per share, according to documents filed with the Securities and Exchange Commission. Last month, Akers entered into an in-licensing and product development deal for a coronavirus vaccine candidate under development by Premas Biotech.

The Asset Integrity Management Systems (AIMS) Market Report renders deep perception of the key regional market status of the Asset Integrity Management Systems

Aker Solutions reported first-quarter revenue of NOK 6.5 billion, a decline of 10 percent compared with the first quarter 2019, as the impact of the COVID-19 outbreak and sharp decline in oil prices impacted activity levels.

Akers Biosciences, Inc. (the “Company”) (AKER), a developer of rapid health information technologies, today announced it will hold a conference call to discuss the licensing announcement with Premas Biotech for a Coronvirus vaccine candidate. Global biotech executive, co-founder and managing director at Premas, Dr. Prabuddha Kundu M.D., will discuss the process underway to seek fast track development of a vaccine candidate and related milestones that we hope to achieve and plan to announce as we progress. To access the replay, please dial 1-844-512-2921 in the U.S. and 1-412-317-6671 for international callers.

Akers Biosciences, Inc. (the “Company”) (AKER), a developer of rapid health information technologies, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 1,366,856 shares of the Company’s common stock, at a purchase price of $3.53 per share, in a registered direct offering priced at-the-market under Nasdaq rules. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds to the Company from this offering are expected to be approximately $4.8 million, before deducting the placement agent’s fees and other offering expenses payable by the Company.

The global Omega 3 Products Market is projected to exhibit a healthy CAGR during the forecast period. The development momentum wills fast-track during the course of the forecast. The Omega-3 is an essential fatty acid (EFA). It is likewise recognized as a pol…

Novel elements of Aker Solutions’ carbon capture technology and potential technological risks were evaluated and mitigation identified. Documentation was reviewed to provide a better understanding of the technology and the specific application and conditions.

The company, which develops and markets point-of-care diagnostic products, is continuing to evaluate 'strategic business alternatives.'

The collapse in oil prices to 21-year lows has led potential buyers of oil and gas fields to try and renegotiate deals already agreed at higher prices, with the first examples emerging of sellers having their hand forced. At a time when most oil companies are…

Internet of Things (IoT) Professional Services Market 2020 Impact, Future Growth Analysis and Challenges | Weatherford International, Halliburton, GE(Baker Hughes) and Others  Latest Herald

The collapse in oil prices to 21-year lows has led potential buyers of oil and gas fields to try and renegotiate deals already agreed at higher prices, with the first examples emerging of sellers having their hand forced.

Akers Biosciences, Inc. (the “Company” or “we”) (AKER), a developer of rapid health information technologies, today announced the closing of its previously announced public offering of 613,500 common units at a public offering price of $4.00 per unit and 1,376,500 pre-funded units at a public offering price of $3.9999 per pre-funded unit, raising gross proceeds of $7.96 million, before deducting placement agent’s fees and other estimated offering expenses payable by Akers, assuming none of the preferred stock warrants issued in this offering are exercised. H.C. Wainwright & Co. is acted as exclusive placement agent for the offering. Each unit sold in this offering is comprised of one share of common stock and one preferred stock warrant to purchase one share of Series C Convertible Preferred Stock.

Akers Biosciences, Inc. (the “Company”) (AKER), a developer of rapid health information technologies, today announced that it reached a settlement agreement to settle two shareholder derivative actions: Watts v. Gormally, et al., No. 2:18-15992 (D.N.J.) and Chan v. Gormally, et al., No. 2:19-cv-4989 (D.N.J.). As previously reported, on October 2, 2019, the plaintiffs filed a motion for preliminary approval of the settlement. On January 8, 2020, the court entered an order that, among other things, granted preliminary approval of the settlement, approved the form and content of the parties' proposed notice of the settlement, directed the Company to issue a press release containing the information in that notice by today, and scheduled a hearing on May 28, 2020 to consider final approval of the settlement.

Akers Biosciences, Inc. (the “Company”) (AKER), a developer of rapid health information technologies, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 766,667 shares of the Company’s common stock, at a purchase price of $6.00 per share, in a registered direct offering priced at-the-market under Nasdaq rules. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds to the Company from this offering are expected to be approximately $4.6 million, before deducting the placement agent’s fees and other offering expenses payable by the Company.

The first quarter of 2020 was an extraordinary quarter. Aker BP delivered strong operational performance and set a new production record. This was however overshadowed by the COVID-19 pandemic and the sharp drop in global oil prices. The company's key priorit…

High borrowing fees are a red flag for a stock. I compiled a list of stocks that have 50%+ fees to borrow (for shorting). Canadian cannabis and corona-related s

Akers Biosciences, Inc. (the “Company”) (AKER), a developer of rapid health information technologies, today announced that its collaboration with Premas Biotech has successfully completed a second milestone, the successful expression of the three coronavirus antigens, Spike (S), Envelope (E), and Membrane (M), that were selected for their vaccine candidate. The antigens have been expressed using the D-CryptTM platform at Premas Biotech, which utilizes its vectors and S cerevisiae strain. Premas is now moving forward with purification and post-expression processing, which we believe should lead to a scaling up of the antigens.

Akers Biosciences, Inc. (the “Company”) (AKER), a developer of rapid health information technologies, today announced that it has acquired a licensing agreement with Premas Biotech, under which Akers will in-license a novel coronavirus vaccine candidate under development by Premas using Premas’ genetically engineered S. cerevisiae platform, D-Crypt™, and partner with Premas to ultimately seek FDA approval. The current global crisis has created the potential for an expedited review process from the FDA, which has recently noted its willingness to fast-track human clinical trials for certain coronavirus candidates.

Oyvind Eriksen is the CEO of Aker ASA (OB:AKER). First, this article will compare CEO compensation with compensation...

The point-of-care test kit company has in-licensed an experimental vaccine under development for the coronavirus.

Akers Biosciences, Inc. (the “Company”) (AKER), a developer of rapid health information technologies, announced today that on December 10, 2019, it received notice from the Hearings Advisor of the Nasdaq Office of General Counsel that the Company successfully regained compliance with the minimum bid price requirements set forth under Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market and that the Company is in compliance with all other applicable listing standards.

The "Omega 3 Market Size, Share & Trends Analysis Report by Type (EPA, DHA, ALA), by Source (Marine Source, Plant Source), by Application, by Region, and Segment Forecasts, 2020-2027" report has been added to ResearchAndMarkets.com's offering.

The collapse in oil prices to 21-year lows has led potential buyers of oil and gas fields to try and renegotiate deals already agreed at higher prices, with the first examples emerging of sellers having their hand forced. At a time when most oil companies are…

Akers Biosciences Inc (NASDAQ: AKER), which said earlier this week that it is one step closer to identifying a coronavirus vaccine candidate, announced another successful milestone Wednesday in its vaccine development program.The New Jersey-based company said that it, along with developmental partner Premas Biotech, has successfully completed the second milestone of successful expression of the three coronavirus antigens -- spike, envelop and membrane --selected for their vaccine candidate.Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter."The antigens have been expressed using the D-CryptTM platform at Premas Biotech, which utilizes its vectors and S cerevisiae strain," according to Akers. Premas will now move ahead with purification and post-expression processing that will lead to a scaling up of the antigen, according to a press release. The company is now halfway through a four-milestone plan that it believes will lead to the commencement of clinical trials, Akers Executive Chairman Christopher Schreiber said in a statement. Akers shares were advancing 6.14% to $6.05 at the time of publication Wednesday. Related Links:Analyst Projects Over 130% Upside In This Biopharma Teva Analyst Says Shares Are Pricing In Too Much Risk See more from Benzinga * The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index * The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

New York, New York--(Newsfile Corp. - April 24, 2020) - Akers Biosciences (NasdaqCM: AKER) announced a licensing agreement with Premas Biotech to find an effective vaccine for COVID-19. Premas Biotech has over 125 employees and has delivered over 650 proteins and has completed over 240 separate projects for pharmaceutical companies. The company also has four candidates currently in clinical trials globally, and most notable, an oral insulin drug candidate which recently completed a Phase ...

Norwegian engineering company Aker Solutions has had its carbon-capture technology approved for use at Norcem's cement plant in Brevik, it said on Wednesday.

Akers and Premas Biotech are three steps into a four-step plan that could lead to clinical trials of a vaccine candidate.

Through leasing it out, Boston Dynamics has opened up the door to possibilities. The post Spot the Robot Dog Can Do Much More Than Fetch Sticks… appeared first on The Good Men Project.

THOROFARE, NJ / ACCESSWIRE / December 10, 2019 / Akers Biosciences, Inc. (NASDAQ:AKER), will be presenting at this year's Investor Summit on December 17 th in Philadelphia. The Investor Summit will take ...